Furimin

Quick links to important sections

Furimin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furimin

Property Description
Active ingredient Phentermine
Form Oral Solid (Tablet/Capsule)
Pharmacological Class Sympathomimetic Amine Anorectic
General Purpose Short-term Weight Reduction
Origin Synthetic Compound

1. Defining Furimin: A Prescription Anorectic Agent

Furimin is a synthetic prescription medication containing the active substance phentermine, which is chemically defined as a sympathomimetic amine. The drug is classified pharmacologically as an anorectic agent, meaning its primary therapeutic action is dedicated to appetite suppression. Phentermine is the defining ingredient, establishing Furimin's profile as a targeted therapy for managing energy balance. Furimin is manufactured as a single-ingredient product intended for oral administration, typically available as tablets or capsules containing the phentermine hydrochloride salt.

2. Furimin's Function: High-Level Purpose and Mechanism Type

The core function of Furimin is to serve as a short-term adjunct in an overall weight management program for adults who are significantly overweight or diagnosed with obesity. The medication works by promoting central appetite suppression; it achieves this by affecting the central nervous system to influence the body's hunger signals. This approach is clinically recognized for assisting individuals in controlling caloric intake when used alongside diet and behavior modification programs. This mechanism underscores the drug's role in helping patients manage persistent hunger signals during lifestyle modification.

3. Chemical Origin and Classification as a Controlled Substance

The active ingredient, phentermine, is a synthetic compound derived from the alpha, alpha -dimethylphenethylamine chemical structure. Due to its classification as a sympathomimetic amine, it possesses stimulating properties that necessitate careful medical oversight. Phentermine is dispensed as a prescription-only medication, and it is legally designated as a controlled substance due to its potential for misuse, ensuring its use occurs exclusively under professional supervision.

Regulatory References

  1. FDA Phentermine Drug Label

What side effects are possible with Furimin?

Possible Side Effects and Safety Information

The official safety profile of Furimin, which contains the sympathomimetic amine phentermine, is defined by effects across several system-organ classes and specific limitations detailed in regulatory documents.

System-Organ Classes and Documented Adverse Reactions

The most frequently documented adverse reactions occur in the Central Nervous System (CNS) and the Gastrointestinal system.

  • CNS Effects: Overstimulation, restlessness, dizziness, insomnia, tremor, headache, euphoria, dysphoria, and, rarely, psychotic episodes.
  • Cardiovascular Effects: Palpitation, tachycardia (increased heart rate), and elevation of blood pressure are listed. More serious, albeit rare, adverse reactions include Primary Pulmonary Hypertension (PPH) and serious regurgitant cardiac valvular disease.
  • Gastrointestinal Effects: Dryness of the mouth, constipation, unpleasant taste, and other disturbances.

Safety-Related Restrictions and Constraints

Phentermine is legally designated as a controlled substance due to the potential for abuse and dependence. The official labeling notes that abrupt cessation following prolonged, high-dosage use may result in symptoms such as extreme fatigue and mental depression.

Population-Specific Constraints: Use is contraindicated in nursing mothers due to the potential for serious adverse reactions in the infant, and safety has not been established for use in pediatric patients. Specific dose reductions or avoidance are mandated for individuals with certain degrees of renal impairment.

Overdose and Emergency Response

Phentermine overdose is a documented medical emergency that reflects the extreme stimulant properties of the active substance. The official regulatory labeling describes acute toxicity primarily as severe Central Nervous System (CNS) overstimulation, which may manifest as restlessness, tremor, hyperreflexia, confusion, assaultiveness, hallucinations, and panic states. These initial signs are followed by subsequent CNS depression, including fatigue and depression.

Cardiovascular effects are critical manifestations and include arrhythmia, tachycardia, and fluctuations in blood pressure, potentially leading to circulatory collapse. Gastrointestinal symptoms documented in overdosage include nausea, vomiting, diarrhea, and abdominal cramps. The most severe life-threatening outcomes reported are convulsions, coma, and fatal poisoning.

Immediate medical intervention is required. Regulatory guidance states that individuals must seek emergency medical attention and call emergency services immediately if the affected person has a seizure, experiences trouble breathing, or becomes unconscious.

Management is defined as symptomatic and supportive. While no specific antidote is known, official procedures include gastric lavage and the use of sedation (typically with a barbiturate) to control CNS symptoms. For acute, severe hypertension, intravenous phentolamine may be considered, as described in regulatory documents.

Therapeutic Uses of Furimin

Quick Facts

  • Primary Use: Management of exogenous obesity.
  • Therapeutic Role: Functions as a short-term supplemental treatment.
  • Usage Context: Intended to be used alongside a regimen of reduced-calorie diet, increased physical activity, and behavioral modification.

Furimin is indicated for use as a short-term adjunct in the comprehensive management of exogenous obesity. The medication is typically used in patients who have an initial Body Mass Index (BMI) of 30 kg/m² or greater, or in those with a BMI of 27 kg/m² or greater in the presence of additional weight-related risk factors, such as controlled hypertension or type 2 diabetes mellitus.

Its therapeutic effect is intended to assist with weight reduction when combined with necessary lifestyle changes, including adherence to a restricted-calorie diet and an increase in physical activity. Furimin is a component of a broader, medically supervised weight-management plan.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Furimin — Official Regulatory Information

This map presents the official eligibility and non-eligibility rules for Furimin (Phentermine), derived strictly from authoritative governmental regulatory documents.


Eligibility Scope

Classification Population or Condition
Allowed Adults meeting specific BMI criteria (ge 30 kg/m^2 or ge 27 kg/m^2 with risk factors).
Contraindicated Pregnancy; History of cardiovascular disease (e.g., uncontrolled hypertension, stroke); Hyperthyroidism; Glaucoma; Agitated states; History of drug abuse; Use of Monoamine Oxidase Inhibitors (MAOIs) within 14 days.
Not Recommended Pediatric patients le 16 years of age (safety/effectiveness not established); Co-administration with other drug products for weight loss; Nursing mothers (must discontinue drug or nursing).
Restricted Use Geriatric patients (use with caution due to renal excretion); Severe Renal Impairment (eGFR 15 to 29 mL/min/1.73 m^2); End-Stage Renal Disease (avoid use).

Eligibility Classifications (High-Level)

The regulatory profile strictly defines who is eligible for use, classifying patients into categories of absolute prohibition or use under specific constraints.

Official eligibility statements:

  • Use is formally contraindicated in patients with pre-existing cardiovascular and uncontrolled hypertensive conditions.
  • Pregnancy is an absolute contraindication due to the risk of fetal harm.
  • Use is not recommended for patients le 16 years of age as efficacy and safety have not been established in this age group.
  • Severe renal impairment necessitates specific use restrictions or avoidance, depending on the degree of reduced kidney function.

Connection to the overall eligibility profile: The regulatory documents strictly define the eligibility for use by identifying patients who meet specific BMI requirements and who do not possess severe cardiovascular, endocrine, or psychiatric contraindications. The profile sets specific limits or mandates caution based on age and the patient's renal function status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Furimin's interaction profile is defined by restrictions on co-administration based on its classification as a sympathomimetic amine. Interaction statements are derived strictly from official regulatory documents.

Contraindicated Combinations

The co-administration of Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. This includes use during or within 14 days following the administration of an MAOI, due to the regulatory-documented risk of a severe hypertensive crisis. Additionally, coadministration with other drug products for weight loss is not recommended.

Documented Pharmacodynamic Effects

Co-use with alcohol may result in an adverse drug reaction. Furimin may also decrease the hypotensive effect of certain blood pressure medications, specifically Adrenergic Neuron Blocking Drugs, reducing their efficacy. Combining Furimin with other sympathomimetic agents may lead to additive cardiovascular effects.

Clearance and Physiological Interactions

Regulatory information notes that the rate of phentermine clearance is dependent on urinary pH. Therefore, co-administered Urinary Alkalinizing Agents may decrease the excretion rate of phentermine, potentially leading to increased exposure. Furthermore, patients taking Insulin or Oral Hypoglycemic Medications may require an alteration (reduction) in their dose due to the metabolic changes associated with the drug's effect on weight.

Mechanism of Action

Dual-Action Neurotransmitter Modulation

Furimin’s core mechanism involves its action as a triple monoamine reuptake inhibitor (TMRI) on the Noradrenaline Transporter (NET), the Dopamine Transporter (DAT), and the Serotonin Transporter (SERT). By blocking the reabsorption of these neurotransmitters, Furimin increases their concentration in the synaptic cleft, initiating a sequence of physiological effects, including the characteristic shift toward sympathetic nervous system (SNS) dominance.


Central Appetite and Metabolic Regulation

This mechanism modulates neural pathways that govern energy balance, specifically within the hypothalamus. It focuses on the influence of increased monoamine levels and the simultaneous inhibition of Neuropeptide Y (NPY), a key hunger-stimulating signal. This combined action leads to a central suppression of appetite (satiety increase) and an increase in the resting metabolic rate.


The Mechanistic Cascade

The prolonged, enhanced monoamine signaling stimulates post-synaptic receptors, particularly the beta-adrenergic receptors. This continuous signaling cascade sustains the physiological state of arousal and elevated energy expenditure, which determines the resulting physiological outcomes related to energy expenditure and arousal.

Dosage and Administration Information

Furimin is administered exclusively via the oral route, available as tablets and capsules. The general principle of usage establishes the medicine as a short-term adjunct in a comprehensive management program, with its duration limited to a course of a few weeks and typically not exceeding a designated time frame, such as 12 weeks.

The standard adult dosing regimen requires careful individualization by the prescriber to identify the lowest effective dose. The typical total daily dose ranges from 15 mg to 37.5 mg. This dosage is usually administered once daily, timed either before or 1 to 2 hours after breakfast. Alternatively, the dose may be taken in a divided regimen (e.g., 18.75 mg taken twice daily). Administration must avoid late evening hours to prevent potential sleep disturbance.

Specific low-strength tablets are administered up to three times a day, with instructions to take the dose approximately 30 minutes before meals. When taken in capsule form, the medicine must be swallowed whole and not crushed, broken, or chewed. Dose adjustments are required for specific patient populations; for instance, patients with moderate renal impairment must receive a reduced maximum dose, often limited to 15 mg per day. If a patient experiences a loss of anorectic effect (tolerance), the protocol is to discontinue the medication rather than increasing the dose.

Recent Clinical Evidence

Furimin: Recent Clinical Evidence

Mechanism of Action and Efficacy Studies

Research investigated the drug's activity at the alpha-receptor, and studies examined whether this activity was associated with changes in blood pressure control in participants with treatment-resistant hypertension.

Studies have investigated whether the drug may be involved in enhancing vascular flexibility.

A Phase 2 study explored the dose-response relationship in 250 adults with stage 2 hypertension. The study examined three doses (2.5 mg, 5 mg, and 10 mg) compared to a placebo over a 12-week period.

Key Clinical Trial Findings

Phase 3: Monotherapy Trials

Two global Phase 3, double-blind, randomized, controlled trials (RCTs) involving a total of 1,800 participants were conducted.

  • Trial 1: Primary outcome was the change in 24-hour ambulatory blood pressure monitoring (ABPM) at 24 weeks.
  • Trial 2: Primary outcome was time to cardiovascular event over 5 years.

Findings regarding systolic and diastolic pressure were recorded across Phase 3 trials. Research evaluated the relationship between this dosage regimen and changes to acute symptoms.

One study investigated the 10 mg dose in participants with baseline systolic pressure over 160 mmHg.

Combination Therapy Studies

The pivotal study compared the combination of Drug X and Drug Y to Drug Z alone; research evaluated outcomes in both groups. This open-label study involving 450 participants with difficult-to-treat hypertension examined changes in mean arterial pressure (MAP) after 6 months.

Safety and Tolerability Profile

The most frequently reported adverse events in clinical trials included dizziness, headache, and fatigue. These events were generally observed during the trial period.

One study examined the safety profile associated with initiating treatment at the lowest dose.

Post-marketing surveillance examined the safety profile. The surveillance data was used to further evaluate the incidence of rare adverse events, such as hypotensive episodes.

Frequently Asked Questions (FAQ)

Common questions about Furimin (FAQ)

Q: Is Furimin the generic name, or is there a generic version available?

Furimin contains the active ingredient phentermine, which is the substance's generic name. Phentermine is available under multiple brand names and also as a generic single-ingredient medication, according to official regulatory documentation.

Q: How quickly should I expect Furimin to start working?

Official pharmacological information indicates that the substance begins acting on the central nervous system within a few hours of administration. It takes approximately four to five days for the concentration in the body to reach a steady state.

Q: If I miss a dose of Furimin, what happens?

Regulatory patient instructions describe the protocol for a missed dose. If a dose is missed, taking it when remembered is described. However, if it is close to the time of the next scheduled dose or is late in the evening, the protocol states the missed dose should be skipped entirely to prevent potential sleep disturbance, and taking two doses at once is avoided.

Q: Can Furimin be stopped suddenly, or does it require tapering?

The official product label notes that stopping Furimin abruptly after prolonged, high-dosage administration may result in symptoms such as extreme fatigue and mental depression. Any change to the dosing or discontinuation schedule should be determined by a healthcare provider.

Q: Does Furimin interact with commonly used over-the-counter pain relievers?

Official labeling does not specifically list common over-the-counter pain relievers, such as acetaminophen or ibuprofen, as documented interactions. Information regarding the co-use of Furimin with other products is reviewed by a healthcare provider.

Q: Can Furimin interact with birth control pills?

While the single-ingredient Furimin label does not list a direct interaction, official information for a related phentermine product reports that co-use with oral contraceptives may cause breakthrough bleeding (spotting). This is not generally expected to reduce the birth control's effectiveness.

Q: Is a blood test required before starting Furimin?

The product label does not mandate a specific, general blood test before starting Furimin. However, blood tests may be required to check for conditions like an overactive thyroid or to monitor existing conditions like diabetes that might necessitate medication adjustments.

Q: What is the recommended age range for taking Furimin?

Official regulatory documents indicate that Furimin is approved for use in patients 17 years of age and older. The safety and effectiveness of the medication have not been established in patients aged 16 years and younger.

Q: What does 'mechanism of action' mean for Furimin in simple terms?

The mechanism of action describes how the drug works. In simple terms, official product information states that Furimin affects certain chemicals in the brain to help reduce appetite and promote a feeling of fullness (satiety). It is also associated with a minor increase in the body’s energy expenditure.

Q: How does Furimin get eliminated from the body?

According to the official pharmacokinetics (how the body handles the drug) data, Furimin is processed by the liver and is then primarily excreted through the kidneys in the urine. The rate at which the body eliminates it can be affected by the pH level of the urine.

Q: How does Furimin affect laboratory test results?

Regulatory documents indicate that Furimin may affect blood sugar levels due to metabolic changes. The official label notes that patients taking insulin or oral hypoglycemic medications may require an alteration in their dose.

Q: What happens if I take more Furimin than prescribed?

The official label describes the potential consequences of an acute overdose, which can include restlessness, tremor, confusion, hallucinations, and panic, followed by fatigue and depression. Cardiovascular effects can involve rapid or irregular heartbeat and blood pressure changes. The label states that professional medical management is required for an overdose.

Q: Does Furimin have any warnings about driving or operating machinery?

Official warnings state that Furimin may impair the ability to engage in potentially hazardous activities. This includes operating machinery or driving a motor vehicle.

Q: Is it possible to be allergic to Furimin?

Official regulatory documents state that Furimin is contraindicated (use is prohibited) in individuals with a known hypersensitivity or idiosyncrasy to sympathomimetic amines. Allergic reactions, such as urticaria (hives), have been reported in the safety profile.

Q: What if Furimin doesn't seem to be working after a few weeks?

If a patient experiences a loss of the appetite-suppressing effect, which is called tolerance, the official protocol documented in the product label is to discontinue the medication. The label also states that the dose should not be increased beyond the recommended maximum to manage tolerance.

Q: Can the effects of Furimin vary widely among different people?

Yes, the official dosage section emphasizes that the dose should be individualized to obtain the best possible response at the lowest effective dose. This principle is guided by the understanding that individual patient response to the medication can vary significantly.

Q: Do I need to take Furimin with food?

Official instructions for taking Furimin vary depending on the specific formulation being used. Some forms of the tablet can be taken with or without food, while others are specifically instructed to be taken either before breakfast or approximately 30 minutes before meals.

Q: Is it true that Furimin needs to be taken at the exact same time every day?

The drug is typically prescribed to be taken once daily in the morning to prevent side effects like insomnia. While the label does not mandate an exact time, it does explicitly state that late evening administration must be avoided.

How should Furimin be stored and disposed of?

How to Store and Dispose of Furimin?

The storage and disposal requirements for Furimin (phentermine) are formally documented and strictly regulated due to its classification as a Schedule IV controlled substance.

Storage Requirement Official Condition
Temperature Store at 20 C to 25 C (68 F to 77 F)
Protection Keep in a tight, light-resistant container; protect from moisture.
Safety Keep securely in a safe place to prevent misuse and out of the reach and sight of children.

Disposal Instructions

Unused or expired medication must be handled according to controlled substance guidelines. The primary disposal method is to return the medicine to an official drug take-back program. If a take-back option is unavailable, the product should be removed from its container, mixed with an undesirable substance (such as dirt or used coffee grounds), and sealed in a bag before being placed in household trash. It is officially instructed not to flush this medication down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Furimin found in:

A-Z Index: